Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYX-5219 in Healthy Volunteers and Participants With Atopic Dermatitis
NCT07558668Phase 1Recruiting
- Sponsor
- Sitryx
- Start
- Feb 2025
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 1, randomised, double-blind trial of SYX-5219 in atopic dermatitis (AD) (3 arms), sponsored by Sitryx. Primary endpoint: Treatment-Emergent Adverse Events at Day 56. Started Feb 2025; status: recruiting.
02
Drugs
SYX-5219
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT07558668.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07558668.